{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:30:02Z","timestamp":1761863402974},"reference-count":25,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,12,18]],"date-time":"2014-12-18T00:00:00Z","timestamp":1418860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>The aim of the study was to identify factors associated with the time between opportunistic disease (<jats:styled-content style=\"fixed-case\">OD<\/jats:styled-content>) diagnosis and antiretroviral therapy (<jats:styled-content style=\"fixed-case\">ART<\/jats:styled-content>) initiation in <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u2010infected patients presenting for care with an <jats:styled-content style=\"fixed-case\">OD<\/jats:styled-content>, and to evaluate the outcomes associated with any delay.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A multicentre cohort study was undertaken in <jats:styled-content style=\"fixed-case\">L<\/jats:styled-content>ondon, Paris and <jats:styled-content style=\"fixed-case\">L<\/jats:styled-content>ille\/<jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>ourcoing. The medical records of patients diagnosed from 2002 to 2012 were reviewed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 437 patients were enrolled in the study: 70% were male, the median age was 40 years, 42% were from sub\u2010Saharan Africa, 68% were heterosexual, the median <jats:styled-content style=\"fixed-case\">CD4<\/jats:styled-content> count was 40\u2009cells\/\u03bcL, and the most common <jats:styled-content style=\"fixed-case\">ODs<\/jats:styled-content> were <jats:italic><jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>neumocystis<\/jats:italic> pneumonia (37%), tuberculosis (24%), toxoplasmosis (12%) and <jats:styled-content style=\"fixed-case\">K<\/jats:styled-content>aposi's sarcoma (11%). Of these patients, 400 (92%) started <jats:styled-content style=\"fixed-case\">ART<\/jats:styled-content> within 24 weeks after <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> diagnosis, with a median time from <jats:styled-content style=\"fixed-case\">OD<\/jats:styled-content> diagnosis to <jats:styled-content style=\"fixed-case\">ART<\/jats:styled-content> initiation of 30 [interquartile range (<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content>) 16\u201358] days. Patients diagnosed between 2009 and 2012 had a shorter time to <jats:styled-content style=\"fixed-case\">ART<\/jats:styled-content> initiation than those diagnosed in earlier years [hazard ratio (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>) 2.07; 95% confidence interval (<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>) 1.58\u20132.72]. Factors associated with a longer time to <jats:styled-content style=\"fixed-case\">ART<\/jats:styled-content> initiation were a CD4 count\u2009\u2265\u2009200\u2009cells\/\u03bcL (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content> 0.30; 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 0.20\u20130.44), tuberculosis (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content> 0.40; 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 0.30\u20130.55) and diagnosis in London (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content> 0.62; 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 0.48\u20130.80). Patients initiating \u2018deferred\u2019 <jats:styled-content style=\"fixed-case\">ART<\/jats:styled-content> (by \u2265\u200930 days) exhibited no difference in disease progression or immunovirological response compared with patients who had shorter times to <jats:styled-content style=\"fixed-case\">ART<\/jats:styled-content> initiation. Patients in the \u2018deferred\u2019 group were less likely to have <jats:styled-content style=\"fixed-case\">ART<\/jats:styled-content> modifications (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content> 0.69; 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 0.48\u20131.00) and had shorter in\u2010patient stays (mean 14.2 days shorter; 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 8.9\u201319.5 days) than patients in the group whose <jats:styled-content style=\"fixed-case\">ART<\/jats:styled-content> was not deferred.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The time between <jats:styled-content style=\"fixed-case\">OD<\/jats:styled-content> diagnosis and <jats:styled-content style=\"fixed-case\">ART<\/jats:styled-content> initiation remains heterogeneous and relatively long, particularly in individuals with a high <jats:styled-content style=\"fixed-case\">CD4<\/jats:styled-content> count or tuberculosis or those diagnosed in <jats:styled-content style=\"fixed-case\">L<\/jats:styled-content>ondon. Deferring <jats:styled-content style=\"fixed-case\">ART<\/jats:styled-content> was associated with fewer <jats:styled-content style=\"fixed-case\">ART<\/jats:styled-content> modifications and shorter in\u2010patient stays.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.12201","type":"journal-article","created":{"date-parts":[[2014,12,19]],"date-time":"2014-12-19T09:00:17Z","timestamp":1418979617000},"page":"219-229","source":"Crossref","is-referenced-by-count":6,"title":["<i>Time to initiation of antiretroviral therapy in <scp>HIV<\/scp>\u2010infected patients diagnosed with an opportunistic disease: a cohort study<\/i>"],"prefix":"10.1111","volume":"16","author":[{"given":"L","family":"Deconinck","sequence":"first","affiliation":[{"name":"UCL Research Department of Infection and Population Health University College London  London UK"},{"name":"Decision Sciences in Infectious Disease: Prevention, Control, and Care IAME UMR 1137 Paris Diderot University Sorbonne Paris Cit\u00e9  Paris France"},{"name":"Department of Infectious Diseases Lille School of Medicine Tourcoing Hospital  Tourcoing France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Yazdanpanah","sequence":"additional","affiliation":[{"name":"Decision Sciences in Infectious Disease: Prevention, Control, and Care IAME UMR 1137 Paris Diderot University Sorbonne Paris Cit\u00e9  Paris France"},{"name":"Department of Infectious Diseases Bichat\u2010Claude Bernard Hospital  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RJ","family":"Gilson","sequence":"additional","affiliation":[{"name":"UCL Research Department of Infection and Population Health University College London  London UK"},{"name":"The Mortimer Market Centre Central and North West London NHS Foundation Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Melliez","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Lille School of Medicine Tourcoing Hospital  Tourcoing France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Viget","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Lille School of Medicine Tourcoing Hospital  Tourcoing France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Joly","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Bichat\u2010Claude Bernard Hospital  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CA","family":"Sabin","sequence":"additional","affiliation":[{"name":"UCL Research Department of Infection and Population Health University College London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,12,18]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1522"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540120802183537"},{"key":"e_1_2_7_4_1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/135965350701200111","article-title":"Frequency, determinants and consequences of delayed access to care for HIV infection in France","volume":"12","author":"Lanoy E","year":"2007","journal-title":"Antivir Ther"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1523"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn169"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005575"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011416"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2012.03991.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0026009"},{"key":"e_1_2_7_11_1","unstructured":"Prise en charge m\u00e9dicale des personnes infect\u00e9es par le VIH recommandations du groupe d'experts rapport2013 Available at http:\/\/www.sante.gouv.fr (accessed 4 December 2014)."},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2011.00944_1.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1993.03500060023008"},{"key":"e_1_2_7_14_1","first-page":"299","article-title":"[NADIS 2000, development of an electronic medical record for patients infected by HIV, HBV and HCV]","volume":"32","author":"Pugliese P","year":"2003","journal-title":"Presse M\u00e9d"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2004.00197.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200205000-00005"},{"key":"e_1_2_7_17_1","unstructured":"Echelle ANRS de Cotation de la Gravit\u00e9 des Ev\u00e9nements Ind\u00e9sirables chez l'adulte version n\u00b06 du 9 septembre2003 Available at http:\/\/www.anrs.fr (accessed 4 December 2014)."},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328314b5f1"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir608"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2011.00954.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09411-4"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013911"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014181"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013607"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir230"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1527"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhiv.12201","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.12201","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T01:24:17Z","timestamp":1696296257000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.12201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,18]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1111\/hiv.12201"],"URL":"https:\/\/doi.org\/10.1111\/hiv.12201","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,18]]}}}